Prostate is the most frequent cancer in men. Prostate cancer progression is driven by androgen steroid hormones, and delayed by androgen deprivation therapy (ADT).
Introduction
Prostate is the most common male gender-specific cancer (1) . Prostate cancer progression is controlled by androgen steroid hormones including testosterone and its active metabolite 5-α dihydroxytestosterone. Androgens stimulate androgen receptor (AR) signalling in prostate cancer cells to control transcription, including of genes that regulate the cell cycle, central metabolism and biosynthesis, as well as housekeeping functions (2) (3) (4) (5) . The roles of both androgens and the AR in transcription have been intensively investigated. However, androgens and the AR also regulate alternative pre-mRNA splicing through still largely unknown mechanisms (6) (7) (8) (9) (10) (11) . This represents a very important knowledge gap: alternative splicing patterns in cancer cells can generate protein isoforms with different biological functions (12) , and is a key process in the generation of biological heterogeneity in prostate cancer (13, 14) .
Androgens are also closely linked to prostate cancer treatment, with androgen deprivation therapy (ADT) being the principal pharmacological strategy for locally advanced and metastatic disease. ADT utilises drugs to inhibit gonadal and extragonadal androgen biosynthesis and additionally competitive AR antagonists block androgen binding and abrogate AR function (4) . ADT delays disease progression, but after 2-3 years tumours often grow again developing castration resistance with a median survival time of 16 months (15) .
The central role of androgens and the AR in prostate cancer, and the poor clinical outlook of castration-resistance prostate cancer (CRPCa), have made it crucially important to identify androgen-regulated target genes and mechanisms of function -particularly those that relate to metastasis. The process of epithelial-mesenchymal transition (EMT) plays a pivotal role in prostate cancer metastasis (16) (17) (18) (19) (20) . While the mechanisms driving EMT in prostate cancer are poorly understood, ADT has recently been shown to directly induce EMT in both mouse and human prostate tissue (21, 22) . Importantly, changes in alternative splicing patterns can have dramatic effects on EMT and on metastatic disease progression (23) .
While the mechanisms through which androgens regulate splicing control are not well understood, splicing itself takes place in the spliceosome, which is a multi-component structure containing a core of essential proteins and small nuclear RNAs (24) . Splicing inclusion of alternative exons is often controlled by splicing regulator proteins that bind either to regulated exons or within their adjacent flanking intron sequences (25) . The estrogen and progesterone steroid nuclear hormone receptors control splicing via recruitment of alternative splicing regulators (including the RNA helicases Ddx5 and Ddx17) (7, 8, 26) , and by changing RNA polymerase II extension rates and chromatin structure to affect splice site selection (27, 28) . Steroid hormones can also drive selection of alternative promoters to include different upstream exons in mRNAs (9, 10) . However, to what extent the above mechanisms may contribute to androgen-mediated splicing is largely unknown.
We reasoned that a potential model to unify the role of androgens and the AR in transcription and splicing control could be via transcriptional regulation of genes that encode splicing regulatory proteins. Using a recently described set of genes that reciprocally change expression in response to androgen stimulation in culture and ADT in patients (29) , here we identify AR-mediated transcriptional control of the key splicing regulator protein Epithelial Splicing Regulator Protein 2 (ESRP2). Importantly, many ESRP2-regulated exons switch splicing in response to androgen stimulation. ESRP2 and its close relative ESRP1 (60% identical to ESRP2 protein) are important regulators of epithelial alternative splicing patterns (12, (30) (31) (32) (33) (34) (35) , reduced expression of which can drive critical aspects of EMT (23, 30, 36) . Our data identify an AR-ESRP2 axis controlling splicing patterns in prostate cancer cells, and further suggest that reduced ESRP2 levels in response to ADT may inadvertently prime prostate cancer cells to facilitate longer term disease progression.
Results

ESRP2 is a direct target for AR regulation in prostate cancer cells
To first gain insight into how androgens may mediate patterns of splicing control we analysed a recently generated dataset of genes that have reciprocal expression patterns on acute androgen stimulation in vitro versus clinical ADT (29) . While a number of genes encoding splicing factors changed expression in response to acute androgen stimulation in vitro, only one such gene ESRP2 also showed a reciprocal expression switch between acute androgen stimulation in culture and ADT in patients (29) . ESRP2 expression decreased following ADT in 7/7 prostate cancer patients (37) ( Figure 1A ). Furthermore, RNAseq data from LTL331 patient-derived xenografts (38) also showed reduced ESRP2 mRNA levels following castration ( Figure 1B ). These data support in vivo androgen-regulation of ESRP2
transcription.
Further analysis of ESRP2 expression patterns in prostate cancer cell lines revealed that ESRP2 is controlled by androgens, but not its close paralog ESRP1. ESRP1 gene expression did not significantly change following castration in the LTL331 patient-derived xenografts (38) . Western blots detected high endogenous levels of both ESRP1 and ESRP2 levels within the AR positive LNCaP and CWR22 RV1 prostate cancer cell lines, as compared to the AR negative PC3 and DU145 prostate cancer cell lines ( Figure 1C and 1D ).
qPCR analysis showed that ESRP2 gene expression in the AR-positive LNCaP cell line was activated in response to androgens, but no androgen effect was observed for ESRP1 gene expression ( Figure 1E ). Androgen mediated-control of ESRP2 expression was also detected in two additional AR-expressing prostate cell lines VCaP and RWPE-1 ( Figure 1F ). Induced ESRP2 protein expression was detected 48 hours after androgen exposure, with ESRP1 protein levels not changing over this same time period ( Figure 1G ). The specificity of the ESRP1 and ESRP2 antibodies used in these experiments was confirmed by detection of over-expressed protein and detection of siRNA mediated protein depletion by western blot identified a molecular subgroup of prostate cancers with metastatic potential at presentation (51) . Within this dataset ESRP1 was 2.76 fold up-regulated in the 'metastatic-subgroup' compared to the 'non-metastatic subgroup'. Using RNA from a subset of samples from the Walker et al. study, we confirmed significant (p < 0.05) upregulation of the ESRP1 gene in primary prostate cancer patients presenting with a metastatic biology ( Figure 2C ). ESRP2 gene expression did not significantly increase in the 20 samples studied.
Each of the above data showed that ESRP1 and ESRP2 expression levels are relatively high in primary prostate cancer compared to normal prostate tissue. High ESRP2 expression was not prognostic of disease progression in the TCGA (PRostate ADenocarcinoma) PRAD cohort using KM-express (52), but high expression of ESRP1 associated with a significantly reduced time to first biochemical recurrence (p=0.022) ( Figure 2D ). Previous data have reported up-regulated ESRP1 and ESRP2 proteins in squamous cell carcinoma tumours but their down-regulation at invasive fronts (53) . We tested these same antibodies against ESRP1 and ESRP2 proteins on prostate cancer FFPE tissue and cell blocks, but they did not pass our stringent quality control tests ( (Figure 3 -source data 1).
We experimentally validated splicing switches for 44 predicted ESRP1/ESRP2-controlled exons by RT-PCR analysis, after LNCaP cells were treated with either of two independent sets of siRNA directed against ESRP1 and ESRP2 or control siRNAs ( Figure 3 and Figure 3 source data 2). We also detected similar splicing switches for 37/44 of these skipped exons after jointly depleting ESRP1 and 2 from the AR-positive CWR22 RV1 prostate cancer cell line; and 28/44 of these splicing switches were observed after jointly depleting ESRP1 and 2 from the AR positive PNT2 cells that model the normal prostate epithelium ( Figure 3 and These results experimentally support an androgen-ESRP2 axis controlling splicing patterns in prostate cancer cells. Amongst the genes containing ESRP2-repressed exons that were also skipped in response to androgen stimulation were DOCK7 (exon 23), which encodes a guanine nucleotide exchange factor involved in cell migration ( Figure 4B ) (56); and RPS24
(exon 5), a gene that is highly expressed in prostate cancer ( Figure 4C ) (57) . Amongst the genes containing ESRP-activated exons that were also activated by androgen exposure were MINK1 (exon 18) which encodes a pro-migratory serine/threonine kinase ( Figure 4D ); MAP3K7 (exon 12) which encodes a serine/threonine kinase that regulates signalling and apoptosis, activates NFKappaB, and is lost in aggressive prostate cancer (58, 59) ( Figure   4E ); GRLH1 (exon 5) that encodes a transcription factor involved in epithelial cell functions ( To visualise the amplitude of splicing switches in these exons in response to ESRP2, we plotted PSIs measured in vitro after ectopic expression of ESRP1/ESRP2, versus PSI values after siRNA mediated depletion of ESRP1/ESRP2 ( Figure 5D , using data from Figure 3 and 5D ) and strongly activated in response to androgen stimulation ( Figure 4G ). In the PRAD dataset, levels of FLNB exon 30 splicing inclusion above 0.78 correlated with an increased time to biochemical recurrence, so a more favourable clinical outcome in prostate cancer ( Figure 5F ). Splicing inclusion of the second set of ESRP1/ESRP2-regulated exons that correlated with decreased time to biochemical recurrence are shown in red in Figure 5D . These included exons both activated (GRHL1 exon 5 and MAP3K7 exon 12) and repressed by the AR-ESRP2 axis (DOCK7 exon 23, and RPS24 exon 5D and 5E). Splicing inclusion of the third and smallest set of exons that did not correlate with time to biochemical recurrence are identified with black dots in Figure 5D .
Splicing of a key exon in the FLNB gene is switched by a drug that antagonises AR activity
The above data identified a subset of ESRP2-regulated splicing switches that associated with biochemical recurrence of prostate cancer after treatment. Since ESRP2 expression was repressed in patient prostate cancer tissue by ADT, we next investigated whether AR inactivation may inadvertently modulate splice isoforms in genes important for cancer progression. We focussed this analysis on skipping of FLNB exon 30, which has recently reported to be a key driver of EMT in breast cancer development (62) . Androgen induction of ESRP2 mRNA expression was blocked by the androgen antagonist bicalutamide ( Figure 6B ). ESRP2 protein expression was also reduced by siRNA depletion of the AR ( Figure 6C ). Furthermore, siRNA-mediated depletion of AR also significantly reduced levels of FLNB splicing inclusion from 84% to 69% ( Figure 6D ). Both these data support a scenario where splicing inclusion of FLNB gene exon 30 is modulated in response to ADT as well as androgen stimulation.
Discussion
In this study we report a novel molecular mechanism to explain how androgen steroid hormones control splicing patterns in prostate cancer cells, and that unifies the functions of the AR both as a transcription factor and being able to control splicing. In this model, the AR controls expression of the master splicing regulator protein ESRP2, which then regulates the splicing patterns of key genes important for prostate cancer biology ( Figure 6E ). Amongst the key data supporting this proposed model, we find that ESRP2 is a direct and early target for transcriptional activation by the AR in prostate cancer cells. Furthermore endogenous splice isoform patterns controlled by ESRP1 and ESRP2 target also respond to androgen stimulation, siRNA-mediated depletion of the AR and/or the AR inhibitor bicalutamide (Casodex ® ). While intuitively straightforward, this model is conceptually different from the mechanisms through which estrogen and progesterone have been shown to regulate splicing (via recruitment of splicing regulators as transcriptional cofactors, and by modulation of transcription speeds and chromatin structure).
Androgens are already known to substantially modify the prostate cancer transcriptome at the transcriptional level, with important implications for cell behaviour and cancer progression (29) . The data presented here imply that androgens also have an important role in controlling splicing patterns, particularly those that relate to epithelial functions. Previous studies identified just a small number of alternative exons that are controlled by androgens in prostate cancer cells, none of which overlapped with the current study (9, 11 
Materials and Methods
Cell Culture
Cell culture and androgen treatment of cells was as described previously (11, (69) (70) (71) (72) (73) 
Antibodies
The following antibodies were used for western blotting: Anti-ESRP2 rabbit antibody 
RT-qPCR
Cells were harvested and total RNA extracted using TRI-reagent (Invitrogen, 15596-026),
according to the manufacturer's instructions. RNA was treated with DNase 1 (Ambion) and cDNA was generated by reverse transcription of 500ng of total RNA using the Superscript VILO cDNA synthesis kit (Invitrogen, 11754-050). Quantitative PCR (qPCR) was performed in triplicate on cDNA using SYBR® Green PCR Master Mix (Invitrogen, 4309155) using the (IDT (51-01-14-04)). AR esiRNA was as described previously (29) .
Immunohistochemistry
Freshly cut tissue sections were analysed for immunoexpression using Ventana Discovery Ultra autostainer (Ventana Medical Systems, Tucson, Arizona). In brief, tissue sections were incubated in Cell conditioning solution 1 (CC1, Ventana) at 95°C to retrieve antigenicity, followed by incubation with respective primary antibodies described above. Bound primary antibodies were visualized using UltraMap DAB anti-Rb Detection Kit.
AR-ChIP
LNCaP cells were stimulated with 10 nM R1881 overnight. The ChIP assay was performed using the one step ChIP kit (Abcam ab117138) as per manufacturer's instruction. Briefly, 
Creation of PC3 stable cell lines
The ESRP1 plasmid (PIBX-C-FF-B-ESRP1) was a gift from Prof Russ Carstens (University of Philadelphia. USA) and the ESRP2 plasmid (pBIGi hESRP2-FLAG) from Dr Keith Brown (University of Bristol, UK). PC3 cells were transfected using FuGene ® HD Transfection Reagent as per manufacturer's instructions. Stable transfectants with ESRP1 was selected using 10µg/ml Blasticidin and ESRP2 plasmid was selected using 150ug/ml Hygromycin.
ESRP2 Plasmid was inducible by 2.5ug/ml doxycycline for 48 hours. PC3 ESRP1 overexpressed cells were transfected with pBIGi hESRP2-FLAG plasmid using the same protocol. Sequencing NextSeq High-Output to obtain 2 x 75 bp reads. Quality control of reads was performed using FastQC. Reads were mapped to the hg38 transcriptome using Salmon.
In vitro cell proliferation analysis
Differential gene expression analysis was performed using DESeq2. Percent spliced-in (PSI)
estimates for splicing events were calculated using SUPPA2 (55) based on isoform transcripts per million (TPM) estimates from Salmon (74) . Quantification utilised Gencode gene models (release 28). Differential PSI was calculated using DiffSplice using the empirical method (75) . Events with a delta PSI > 10% and FDR < 0.05 were considered as significant.
PSIchomics and Bioinformatic analysis of PRAD cohort
Clinical expression patterns of ESRP2-regulated exons were monitored using PSIchomics Figure 2C were previously published (51).
Statistical Analyses
All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.).
Statistical analyses were conducted using the GraphPad Prism software (version 5.04/d).
PCR quantification of mRNA isoforms was assessed using the unpaired student's t-test. Data are presented as the mean of three independent samples ± standard error of the mean (SEM).
Statistical significance is denoted as * p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. Interrogation of the TCGA PRAD (PRostate ADenocarcinoma) cohort using KM-express (52) . ESRP1 expression levels linked to a reduced time to PSA biochemical recurrence (bifurcate gene expression at average, log-rank test p=0.022). Over-expression of (E) ESRP1, (F) ESRP2, or (G) both ESRP1 and ESRP2 in PC3 cells significantly slowed the growth of prostate cancer xenografts in vivo. Data were analysed by Two-way ANOVA, and the p value is for the overall difference between two groups. Biological triplicate samples were used for CWR22RV1, PNT2 and LNCaP cells, and technical replicate samples were used for RNAs prepared from PC3 cells. PSI levels were measured using RT-PCR analysis averaged from 3 replicates (mean data given in Figure 3 source data 2), and clustered in the heat map according to splicing patterns across the different conditions. The heatmap was generated using heatmap 2 function using R's 'gplots'
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